$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000162828018005886 Filed on May 04, 2018

Income Statement

Concept	2018 Q1	2017 Q1
Revenue	$1.436M	$235.0K
YoY Change	511.06%	-61.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.670M	$4.330M
YoY Change	-15.24%	-40.03%
% of Gross Profit
Research & Development	$13.95M	$13.87M
YoY Change	0.56%	5.54%
% of Gross Profit
Depreciation & Amortization	$602.0K	$334.0K
YoY Change	80.24%	53.92%
% of Gross Profit
Operating Expenses	$19.84M	$18.53M
YoY Change	7.05%	-9.94%
Operating Profit	-$18.41M	-$18.30M
YoY Change	0.58%	-8.4%
Interest Expense	$104.0K	$42.00K
YoY Change	147.62%
% of Operating Profit
Other Income/Expense, Net	$976.0K	-$328.0K
YoY Change	-397.56%	-107.99%
Pretax Income	-$17.43M	-$18.63M
YoY Change	-6.44%	17.39%
Income Tax
% Of Pretax Income
Net Earnings	-$17.43M	-$18.63M
YoY Change	-6.43%	17.34%
Net Earnings / Revenue	-1213.72%	-7926.38%
Basic Earnings Per Share	-$0.36
Diluted Earnings Per Share	-$0.36	-$343.0K
COMMON SHARES
Basic Shares Outstanding	55.07M shares	55.02M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$172.5M	$110.4M
YoY Change	56.25%	-36.04%
Cash & Equivalents	$12.46M	$29.85M
Short-Term Investments	$160.1M	$80.50M
Other Short-Term Assets	$1.500M	$1.600M
YoY Change	-6.25%	6.67%
Inventory
Prepaid Expenses
Receivables	$719.0K	$7.878M
Other Receivables	$400.0K	$300.0K
Total Short-Term Assets	$175.2M	$120.3M
YoY Change	45.66%	-31.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.83M	$11.46M
YoY Change	3.2%	253.55%
Goodwill	$24.36M	$24.36M
YoY Change	0.0%	-85.01%
Intangibles	$58.65M	$99.45M
YoY Change	-41.03%	-71.8%
Long-Term Investments
YoY Change
Other Assets	$0.00	$12.60M
YoY Change	-100.0%
Total Long-Term Assets	$94.84M	$147.9M
YoY Change	-35.86%	-72.02%
TOTAL ASSETS
Total Short-Term Assets	$175.2M	$120.3M
Total Long-Term Assets	$94.84M	$147.9M
Total Assets	$270.0M	$268.1M
YoY Change	0.7%	-61.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$900.0K	$1.600M
YoY Change	-43.75%	-60.0%
Accrued Expenses	$6.400M	$5.300M
YoY Change	20.75%	55.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.40M	$10.87M
YoY Change	-4.37%	-2.17%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$12.00M
YoY Change	-100.0%
Other Long-Term Liabilities	$10.30M	$14.90M
YoY Change	-30.87%	93.51%
Total Long-Term Liabilities	$10.30M	$26.90M
YoY Change	-61.71%	249.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.40M	$10.87M
Total Long-Term Liabilities	$10.30M	$26.90M
Total Liabilities	$37.61M	$79.04M
YoY Change	-52.42%	-52.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$757.8M	-$669.8M
YoY Change	13.15%	136.79%
Common Stock	$876.3M	$870.8M
YoY Change	0.62%	3.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$232.4M	$189.1M
YoY Change
Total Liabilities & Shareholders Equity	$270.0M	$268.1M
YoY Change	0.7%	-61.87%

Cashflow Statement

Concept	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$17.43M	-$18.63M
YoY Change	-6.43%	17.34%
Depreciation, Depletion And Amortization	$602.0K	$334.0K
YoY Change	80.24%	53.92%
Cash From Operating Activities	-$19.97M	-$17.54M
YoY Change	13.87%	51.87%
INVESTING ACTIVITIES
Capital Expenditures	$248.0K	$3.423M
YoY Change	-92.75%	1140.22%
Acquisitions
YoY Change
Other Investing Activities	-$75.42M	$26.62M
YoY Change	-383.32%	-300.0%
Cash From Investing Activities	-$75.67M	$23.20M
YoY Change	-426.22%	-270.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$66.27M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$54.37M	$354.0K
YoY Change	15257.91%	207.83%
NET CHANGE
Cash From Operating Activities	-$19.97M	-$17.54M
Cash From Investing Activities	-$75.67M	$23.20M
Cash From Financing Activities	$54.37M	$354.0K
Net Change In Cash	-$41.83M	$6.014M
YoY Change	-795.56%	-124.04%
FREE CASH FLOW
Cash From Operating Activities	-$19.97M	-$17.54M
Capital Expenditures	$248.0K	$3.423M
Free Cash Flow	-$20.22M	-$20.96M
YoY Change	-3.55%	77.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2893000	USD
CY2018Q1	abus	Accrued Payroll Current AccruedPayrollCurrent	192000	USD
CY2017Q4	abus	Accrued Research And Development AccruedResearchAndDevelopment	4937000	USD
CY2018Q1	abus	Accrued Research And Development AccruedResearchAndDevelopment	3683000	USD
CY2018Q1	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	-504000	USD
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	2871000	USD
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	3702000	CAD
CY2017Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	1239000	USD
CY2018Q1	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	1188000	USD
CY2017Q4	abus	Employee Stock Options Liability Classified Outstanding Fair Value Disclosure EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure	1239000	USD
CY2018Q1	abus	Employee Stock Options Liability Classified Outstanding Fair Value Disclosure EmployeeStockOptionsLiabilityClassifiedOutstandingFairValueDisclosure	1188000	USD
CY2017Q1	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	1059000	USD
CY2018Q1	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	-848000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	7179000	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	9256000	CAD
CY2006Q2	abus	Number Of Chemotherapy Products With Worldwide Licenses NumberOfChemotherapyProductsWithWorldwideLicenses	3	chemotherapy_products
	abus	Percent Of Costs Funded By Tpc PercentOfCostsFundedByTPC	0.27
CY2017	abus	Restricted Investment Term RestrictedInvestmentTerm	P2Y
CY2018Q1	abus	Royalty Guarantees Commitments Percentage RoyaltyGuaranteesCommitmentsPercentage	0.025
CY2018Q1	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	2	subsidiary
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55051995	shares
CY2018Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10646000	USD
CY2018Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6459000	USD
CY2017Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1987000	USD
CY2018Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	943000	USD
CY2017Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	402000	USD
CY2018Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	719000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	402000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	719000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	429000	USD
CY2018Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1222000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12671000	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13251000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48185000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48185000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42840000	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	43769000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1510000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	135000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5961443	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22095109	shares
CY2017Q4	us-gaap	Assets Assets	237161000	USD
CY2018Q1	us-gaap	Assets Assets	270026000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	129366000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	175186000	USD
CY2017Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	138953000	USD
CY2018Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	172540000	USD
CY2017Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	1059000	USD
CY2018Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-848000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	9065000	USD
CY2017Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10124000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10424000	USD
CY2018Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	9576000	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1427000	USD
CY2018Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23413000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29851000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54292000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12461000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	54292000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	12461000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6438000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-41831000	USD
CY2017Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2018Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55060662	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55087191	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55060662	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55087191	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	876108000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	876288000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	693000	USD
CY2018Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	693000	USD
CY2017Q4	us-gaap	Deferred Revenue DeferredRevenue	2742000	USD
CY2018Q1	us-gaap	Deferred Revenue DeferredRevenue	1720000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2742000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1720000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	16943000	USD
CY2018Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	16943000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	334000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	602000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	424000	USD
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-565000	USD
CY2017Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-22000	USD
CY2018Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
CY2017Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	427000	USD
CY2018Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-526000	USD
CY2017Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	425000	USD
CY2018Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-565000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4328000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3669000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	24364000	USD
CY2018Q1	us-gaap	Goodwill Goodwill	24364000	USD
CY2017Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	340000	USD
CY2018Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	342000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3909000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4187000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7605000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	317000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7392000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1022000	USD
CY2017Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	15000	USD
CY2018Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	2000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	264000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-687000	USD
CY2017Q1	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	0	USD
CY2018Q1	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	1029000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58647000	USD
CY2018Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	58647000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	42000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	104000	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	368000	USD
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	758000	USD
CY2017Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	72060000	USD
CY2018Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	160079000	USD
CY2017Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	42000	USD
CY2018Q1	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	97000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	54688000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	37608000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	237161000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	270026000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14627000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	66265000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10396000	USD
CY2017Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	11663000	USD
CY2018Q1	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	11793000	USD
CY2017Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2018Q1	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2017Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	12001000	USD
CY2018Q1	us-gaap	Long Term Loans Payable LongTermLoansPayable	0	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	354000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54367000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	23195000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-75666000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17535000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19967000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-18627000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-17429000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18627000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19765000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-328000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	976000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	18534000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	19841000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18299000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18405000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	358000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	322000	USD
CY2017Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-26618000	USD
CY2018Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	75418000	USD
CY2018Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	592000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3423000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	248000	USD
CY2017Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2018Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	2336000	USD
CY2017Q4	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	49780000	USD
CY2018Q1	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	118381000	USD
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	500000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	500000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	66265000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2144000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1457000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	103000	USD
CY2017Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	353000	USD
CY2018Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24854000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25080000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11829000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12183000	USD
CY2017Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2018Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	12001000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13872000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13949000	USD
CY2017Q4	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	12601000	USD
CY2018Q1	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	0	USD
CY2017Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	12601000	USD
CY2018Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	0	USD
CY2017Q1	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2018Q1	us-gaap	Restructuring Charges RestructuringCharges	1621000	USD
CY2018Q1	us-gaap	Restructuring Reserve RestructuringReserve	1029000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-738070000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-757835000	USD
CY2017Q1	us-gaap	Revenues Revenues	235000	USD
CY2018Q1	us-gaap	Revenues Revenues	1436000	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	72060000	USD
CY2018Q1	us-gaap	Short Term Investments ShortTermInvestments	160079000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	103000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	182473000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	232418000	USD
CY2017Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2018Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	128000	USD
CY2017Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2018Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1029000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54307464	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55071964	shares
CY2018Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the “Company” or “Arbutus”) is a biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (“HBV”). To pursue its strategy of developing a curative combination regimen, the Company has assembled a pipeline of multiple drug candidates with differing and complementary mechanisms of action targeting HBV. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieve profitable operations. The continuation of the research and development activities and the commercialization of its products are dependent on the Company’s ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of future research and development programs or the Company’s ability to continue to fund these programs in the future.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-18-005886-index-headers.html	Edgar Link	pending
0001628280-18-005886-index.html	Edgar Link	pending
0001628280-18-005886.txt	Edgar Link	pending
0001628280-18-005886-xbrl.zip	Edgar Link	pending
abus-20180331.xml	Edgar Link	completed
abus-20180331.xsd	Edgar Link	pending
abus-20180331_cal.xml	Edgar Link	unprocessable
abus-20180331_def.xml	Edgar Link	unprocessable
abus-20180331_lab.xml	Edgar Link	unprocessable
abus-20180331_pre.xml	Edgar Link	unprocessable
arbutusq12018.htm	Edgar Link	pending
exhibit101genevantmasterag.htm	Edgar Link	pending
exhibit311q12018.htm	Edgar Link	pending
exhibit312q12018.htm	Edgar Link	pending
exhibit321q12018.htm	Edgar Link	pending
exhibit322q12018.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipelineapril2018.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2018 Q1 Form 10-Q Financial Statement

#000162828018005886 Filed on May 04, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2018 Q1 Form 10-Q Financial Statement

#000162828018005886 Filed on May 04, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus